• Skip to primary navigation
  • Skip to main content
  • Skip to footer

LKT Labs

Biochemicals for Life Science Research

  • Products
    • New Products
    • Cancer Biology
    • Cardiovascular
    • Endocrine Signaling and Immunology
    • Metabolic and GI Pathology
    • Microbiology
    • Natural Products
    • Neuroscience
    • Peptides
    • Pharmaceutical Impurities and Derivatives
    • Stem Cell Modulators
  • Services
    • Custom Synthesis
    • Natural Product Isolation
    • Analytical Services
  • Int’l Distributors
  • Support
    • About LKT Labs
    • General Inquiry
    • Bulk Quote Request
    • Document Request
    • Technical Support
    • Catalog Request
    • Product Flyers
  • Contact Us
  • Cart
  • Login / Register
Raloxifene Hydrochloride

Raloxifene Hydrochloride

Product ID R0243
Cas No. 82640-04-8
Purity ≥98%
Product Unit SizeCostQuantityStock
50 mg $90.50 In stock
250 mg $172.20 In stock
500 mg $267.50 In stock
1 g $477.80 In stock
Bulk Quote

Quicklinks

  • Description
  • Product Info
  • Shipping and Storage
  • Downloads
  • References
  • Description
  • Product Info
  • Shipping and Storage
  • Downloads
  • References
  • Custom Order

Description

Raloxifene is a selective estrogen receptor modulator (SERM) that exhibits agonist activity in bone and antagonist activity in uterine and breast tissues. Raloxifene is clinically used to prevent osteoporosis in post-menopausal women and to treat ER+ breast cancer. This compound exhibits anti-osteoporotic, anti-parasitic, neuromodulatory, and anticancer chemotherapeutic activities. Raloxifene decreases fracture risk and enhances bone strength in clinical settings. In vitro and in vivo, raloxifene inhibits growth of Leishmania and parasitic burden. Additionally, raloxifene increases uptake of glutamate and expression of GLT-1 in astrocytes. In animal models of breast cancer, this compound decreases expression of EGFR, vascular density, and tumor growth.

Product Info

Cas No.

82640-04-8

Purity

≥98%

Formula

C28H27NO4S • HCl

Formula Wt.

510.05

Chemical Name

[6-hydroxy-2-(4-hydroxyphenyl)benzo[b]thien-3-yl]- [4-[ 2-(1-piperidinyl) ethoxy] phenyl]methanone hydrochloride

IUPAC Name

[6-hydroxy-2-(4-hydroxyphenyl)-1-benzothiophen-3-yl]-[4-(2-piperidin-1- ylethoxy)phenyl]methanone;hydrochloride

Synonym

Evista

Melting Point

258°C

Solubility

Very slightly soluble in water. Soluble in DMSO at 28 mg/mL.

Appearance

Yellowish Crystalline Powder

Shipping and Storage

Store Temp

Ambient

Ship Temp

Ambient

Downloads

MSDS

R0243 MSDS PDF

Info Sheet

R0243 Info Sheet PDF

References

Karki P, Webb A, Zerguine A, et al. Mechanism of raloxifene-induced upregulation of glutamate transporters in rat primary astrocytes. Glia. 2014 Aug;62(8):1270-83. PMID: 24782323.

Reimão JQ, Miguel DC, Taniwaki NN, et al. Antileishmanial activity of the estrogen receptor modulator raloxifene. PLoS Negl Trop Dis. 2014 May 8;8(5):e2842. PMID: 24810565.

Gallant MA, Brown DM, Hammond M, et al. Bone cell-independent benefits of raloxifene on the skeleton: a novel mechanism for improving bone material properties. Bone. 2014 Apr;61:191-200. PMID: 24468719.

Taurin S, Allen KM, Scandlyn MJ, et al. Raloxifene reduces triple-negative breast cancer tumor growth and decreases EGFR expression. Int J Oncol. 2013 Sep;43(3):785-92. PMID: 23842642.

Gizzo S, Saccardi C, Patrelli TS, et al. Update on raloxifene: mechanism of action, clinical efficacy, adverse effects, and contraindications. Obstet Gynecol Surv. 2013 Jun;68(6):467-81. PMID: 23942473.

Custom Order

  • Size of single unit expressed as number (e.g. '500' in the case of 500 mg)
  • Total quantity of unit size desired (e.g. '10' in the case of 10 x 500 mg). If only one unit is desired, you may leave this blank.
  • This field is for validation purposes and should be left unchanged.

Related Products

  • C000078

    C-178

    STING inhibitor

    ≥99%
  • U6859

    Urocortin III, human

    Endogenous peptide, involved in stress signalin...

    ≥95%
  • C0252

    Canertinib Dihydrochloride

    EGFR inhibitor.

    ≥98%
  • V1745

    Veliparib

    PARP inhibitor.

    ≥99%
  • D1770

    Dermorphin Analog

    Synthetic peptide; dermorphin analog; δOR and ...

    ≥95%
  • G691343

    Griseofulvin

    Fungistatic

    ≥98%
  • P0369

    Parecoxib Sodium

    NSAID; COX-2 inhibitor.

    ≥99%
  • A5378

    Antimycin A

    Oxidative phosphorylation inhibitor.

  • C2844

    Chloramphenicol

    Protein translation inhibitor, peptidyl transfe...

    ≥98%
  • C0006

    Cabozantinib

    VEGFR2, c-Met, RET inhibitor.

    ≥98%
  • G1849

    Gemifloxacin Mesylate

    Fluoroquinolone; bacterial DNA gyrase inhibitor...

    ≥98%
  • C5600

    CO-1686

    EGFR (WT, T790M) inhibitor.

    ≥98%
  • C3352

    Cinacalcet Hydrochloride

    Ca2+-sensing receptor agonist.

    ≥99%
  • G4596

    Glycidamide

    Epoxide metabolite of acrylamide, induces DNA a...

    ≥98%
  • T162051

    Tebipenem

    Broad-spectrum antibiotic

    ≥99%
  • P3576

    Pitavastatin Calcium

    Statin; HMG-CoA reductase inhibitor.

    ≥98%
  • D1773

    Deshydroxy LY-411575

    γ-Secretase inhibitor.

    ≥98%
  • B5074

    BMS-599626

    EGFR, VEGFR inhibitor.

    ≥98%
  • C2943

    Chlorogenic Acid (from Eucommia)

    Polyphenol derivative of caffeic acid found in ...

    ≥98%
  • R5611

    Rocuronium Bromide

    Non-depolarizing NMJ blocker; nAChR and M2/3 mA...

    ≥98%

Footer

  • Contact Us
  • About Us
  • Site Map
  • Terms and Conditions
LKT Laboratories, Inc.
545 Phalen Blvd.
St. Paul MN, 55130

Ph: (888)-558-5227
Fax: (888)-558-7329

©2025 LKT Laboratories, All Rights Reserved - Products for research use only